A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy

Xuejiao Cui; Futao Wang; Cong Liu

doi:10.3389/fimmu.2023.1062045

journal article Open Access Jan 19, 2023

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy

Xuejiao Cui Futao Wang Cong Liu

Frontiers in Immunology Vol. 14 · Frontiers Media SA

View at Publisher Save 10.3389/fimmu.2023.1062045

Abstract

Graves’ orbitopathy (GO) is an organ-specific autoimmune disease, but its pathogenesis remains unclear. There are few review articles on GO research from the perspective of target cells and target antigens. A systematic search of PubMed was performed, focusing mainly on studies published after 2015 that involve the role of target cells, orbital fibroblasts (OFs) and orbital adipocytes (OAs), target antigens, thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R), and their corresponding antibodies, TSHR antibodies (TRAbs) and IGF-1R antibodies (IGF-1R Abs), in GO pathogenesis and the potentially effective therapies that target TSHR and IGF-1R. Based on the results, OFs may be derived from bone marrow-derived CD34+ fibrocytes. In addition to CD34+ OFs, CD34- OFs are important in the pathogenesis of GO and may be involved in hyaluronan formation. CD34- OFs expressing Slit2 suppress the phenotype of CD34+ OFs. β-arrestin 1 can be involved in TSHR/IGF-1R crosstalk as a scaffold. Research on TRAbs has gradually shifted to TSAbs, TBAbs and the titre of TRAbs. However, the existence and role of IGF-1R Abs are still unknown and deserve further study. Basic and clinical trials of TSHR-inhibiting therapies are increasing, and TSHR is an expected therapeutic target. Teprotumumab has become the latest second-line treatment for GO. This review aims to effectively describe the pathogenesis of GO from the perspective of target cells and target antigens and provide ideas for its fundamental treatment.

Topics

No keywords indexed for this article. Browse by subject →

References

117

[1]

Bartalena "The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy" Eur J Endocrinol (2021) 10.1530/eje-21-0479

[2]

Bartalena "Diagnosis and management of graves disease: a global overview" Nat Rev Endocrinol (2013) 10.1038/nrendo.2013.193

[3]

Weiler "Thyroid eye disease: a review" Clin Exp Optom (2017) 10.1111/cxo.12472

[4]

Khamisi "Serum thyroglobulin is associated with orbitopathy in graves’ disease" J Endocrinol Invest (2021) 10.1007/s40618-021-01505-8

[5]

Cao "The risk factors for graves’ ophthalmopathy" Graefes Arch Clin Exp Ophthalmol (2022) 10.1007/s00417-021-05456-x

[6]

Smith "TSHR as a therapeutic target in graves’ disease" Expert Opin Ther Targets (2017) 10.1080/14728222.2017.1288215

[7]

Krieger "TSH/IGF1 receptor crosstalk: mechanism and clinical implications" Pharmacol Ther (2020) 10.1016/j.pharmthera.2020.107502

[8]

Dottore "Association of T and b cells infiltrating orbital tissues with clinical features of graves orbitopathy" JAMA Ophthalmol (2018) 10.1001/jamaophthalmol.2018.0806

[9]

Dottore "Role of the mononuclear cell infiltrate in graves’ orbitopathy (GO): results of a large cohort study" J Endocrinol Invest (2022) 10.1007/s40618-021-01692-4

[10]

Huang "The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy" Eye (Lond) (2019) 10.1038/s41433-018-0279-9

[11]

He "The potential markers involved in newly diagnosed graves’ disease and the development of active graves’ orbitopathy" Cytokine (2020) 10.1016/j.cyto.2020.154998

[12]

Fang "IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO" J Clin Endocrinol Metab (2016) 10.1210/jc.2016-1882

[13]

Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy

Sijie Fang, Yazhuo Huang, Sisi Zhong et al.

The Journal of Clinical Endocrinology & Metabo... 2017 10.1210/jc.2017-01349

[14]

Siomkajlo "Effect of systemic steroid therapy in graves’ orbitopathy on regulatory T cells and Th17/Treg ratio" J Endocrinol Invest (2021) 10.1007/s40618-021-01565-w

[15]

Matsuzawa "Implications of FoxP3-positive and -negative CD4(+) CD25(+) T cells in graves’ ophthalmopathy" Endocr J (2016) 10.1507/endocrj.ej16-0108

[16]

Taylor "New insights into the pathogenesis and nonsurgical management of graves orbitopathy" Nat Rev Endocrinol (2020) 10.1038/s41574-019-0305-4

[17]

Virakul "Integrative analysis of proteomics and DNA methylation in orbital fibroblasts from graves’ ophthalmopathy" Front Endocrinol (Lausanne) (2020) 10.3389/fendo.2020.619989

[18]

Liu "MicroRNA-146a downregulates the production of hyaluronic acid and collagen I in graves’ ophthalmopathy orbital fibroblasts" Exp Ther Med (2020) 10.3892/etm.2020.9165

[19]

Wang "LncRNA LPAL2/miR-1287-5p/EGFR axis modulates TED-derived orbital fibroblast activation through cell adhesion factors" J Clin Endocrinol Metab (2021) 10.1210/clinem/dgab256

[20]

Klett "Differential expression of immunoreactive HLA-DR and ICAM-1 in human cultured orbital fibroblasts and orbital tissue" Opht Plast Reconstr Surg (1996) 10.1097/00002341-199609000-00001

[21]

Hiromatsu "Mechanisms of immune damage in graves’ ophthalmopathy" Horm Res (1987) 10.1159/000180701

[22]

Kozdon "Mesenchymal stem cell-like properties of orbital fibroblasts in graves’ orbitopathy" Invest Ophthalmol Vis Sci (2015) 10.1167/iovs.15-16580

[23]

Wei "Simvastatin and ROCK inhibitor y-27632 inhibit myofibroblast differentiation of graves’ ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways" Front Endocrinol (Lausanne) (2020) 10.3389/fendo.2020.607968

[24]

Perros "Graves’ orbitopathy as a rare disease in Europe: a European group on graves’ orbitopathy (EUGOGO) position statement" Orphanet J Rare Dis (2017) 10.1186/s13023-017-0625-1

[25]

Lacheta "Immunological aspects of graves’ ophthalmopathy" BioMed Res Int (2019) 10.1155/2019/7453260

[26]

Smith "Potential roles of CD34+ fibrocytes masquerading as orbital fibroblasts in thyroid-associated ophthalmopathy" J Clin Endocrinol Metab (2019) 10.1210/jc.2018-01493

[27]

Basak "Peripheral blood mononuclear cells - can they provide a clue to the pathogenesis of graves’ orbitopathy" Endocrine (2022) 10.1007/s12020-021-02865-0

[28]

Lu "CD34- orbital fibroblasts from patients with thyroid-associated ophthalmopathy modulate TNF-alpha expression in CD34+ fibroblasts and fibrocytes" Invest Ophthalmol Vis Sci (2018) 10.1167/iovs.18-23951

[29]

Smith "Gravesd disease" N Engl J Med (2016) 10.1056/nejmra1510030

[30]

van Zeijl "Effects of thyrotropin and thyrotropin-receptor-stimulating graves’ disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of graves’ ophthalmopathy patients" Thyroid (2010) 10.1089/thy.2009.0447

[31]

Mummert "Immunologic roles of hyaluronan" Immunol Res (2005) 10.1385/ir:31:3:189

[32]

Fernando "Slit2 may underlie divergent induction by thyrotropin of IL-23 and IL-12 in human fibrocytes" J Immunol (2020) 10.4049/jimmunol.1900434

[33]

Fernando "Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: potential relevance to thyroid-associated ophthalmopathy" J Clin Endocrinol Metab (2021) 10.1210/clinem/dgaa684

[34]

Fernando "Slit2 modulates the inflammatory phenotype of orbit-infiltrating fibrocytes in graves’ disease" J Immunol (2018) 10.4049/jimmunol.1800259

[35]

Wiersinga "Autoimmunity in graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors" J Clin Endocrinol Metab (2011) 10.1210/jc.2011-0307

[36]

Kim "Transcriptomic profiling of control and thyroid-associated orbitopathy (TAO) orbital fat and TAO orbital fibroblasts undergoing adipogenesis" Invest Ophthalmol Vis Sci (2021) 10.1167/iovs.62.9.24

[37]

Jung "Wnt signalling inhibits adipogenesis in orbital fibroblasts from patients with graves’ orbitopathy" Br J Ophthalmol (2022) 10.1136/bjophthalmol-2020-316898

[38]

Ko "Inhibitory effect of idelalisib, a selective phosphatidylinositol 3-kinase delta inhibitor, on adipogenesis in an in vitro model of graves’ orbitopathy" Invest Ophthalmol Vis Sci (2018) 10.1167/iovs.18-24509

[39]

Ko "PERK mediates oxidative stress and adipogenesis in graves’ orbitopathy pathogenesis" J Mol Endocrinol (2021) 10.1530/jme-21-0057

[40]

Lee "Glycogen synthase kinase-3beta mediates proinflammatory cytokine secretion and adipogenesis in orbital fibroblasts from patients with graves’ orbitopathy" Invest Ophthalmol Vis Sci (2020) 10.1167/iovs.61.8.51

[41]

Hammond "MicroRNA-130a is elevated in thyroid eye disease and increases lipid accumulation in fibroblasts through the suppression of AMPK" Invest Ophthalmol Vis Sci (2021) 10.1167/iovs.62.1.29

[42]

Shin "TGFbeta-treated placenta-derived mesenchymal stem cells selectively promote anti-adipogenesis in thyroid-associated ophthalmopathy" Int J Mol Sci (2022) 10.3390/ijms23105603

[43]

Zhang "Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to graves’ orbitopathy" J Clin Endocrinol Metab (2012) 10.1210/jc.2011-1299

[44]

Billon "Developmental origins of the adipocyte lineage: new insights from genetics and genomics studies" Stem Cell Rev Rep (2012) 10.1007/s12015-011-9242-x

[45]

Gesta "Developmental origin of fat: tracking obesity to its source" Cell (2007) 10.1016/j.cell.2007.10.004

[46]

Ferrari "Novel therapies for thyroid autoimmune diseases: an update" Best Pract Res Clin Endocrinol Metab (2020) 10.1016/j.beem.2019.101366

[47]

Xia "Simultaneous induction of graves’ hyperthyroidism and graves’ ophthalmopathy by TSHR genetic immunization in BALB/c mice" PloS One (2017) 10.1371/journal.pone.0174260

[48]

Choi "Thyroid-stimulating hormone receptor expression on primary cultured human extraocular muscle myoblasts" Curr Eye Res (2018) 10.1080/02713683.2018.1501075

[49]

Smith "Insulin-like growth factor-i receptor and thyroid-associated ophthalmopathy" Endocr Rev (2019) 10.1210/er.2018-00066

[50]

Zhang "Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction" J Biol Chem (2009) 10.1074/jbc.m109.003616

Showing 50 of 117 references

Metrics

48

Citations

117

References

Details

Published: Jan 19, 2023
Vol/Issue: 14
License: View

Authors

Laufer Center for Physical and Quantitative Biology Stony Brook University Stony Brook New York; Department of Chemistry Stony Brook University Stony Brook New York

Cite This Article

Xuejiao Cui, Futao Wang, Cong Liu (2023). A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1062045

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy

You May Also Like